Bernstein raised the firm’s price target on Regeneron (REGN) to $818 from $781 and keeps an Outperform rating on the shares. The firm notes the company appears to have finally found its footing, with good commercial execution on Eylea and Dupixent, combined with an encouraging Eylea HD regulatory update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $865 from $815 at Guggenheim
- Regeneron price target raised to $627 from $543 at BofA
- Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks
- Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges
- Regeneron Pharmaceuticals Reports Q3 2025 Financial Results